Assesment of P wave duration and dispersion in Parkinson's disease
dc.authorid | KOCER, ABDULKADIR/0000-0003-2866-555X | |
dc.contributor.author | Kocer, Abdulkadir | |
dc.contributor.author | Karakaya, Osman | |
dc.contributor.author | Barutcu, Irfan | |
dc.contributor.author | Esen, Ozlem Batukan | |
dc.contributor.author | Kargin, Ramazan | |
dc.contributor.author | Domac, Fusun Mayda | |
dc.date.accessioned | 2024-09-25T19:56:23Z | |
dc.date.available | 2024-09-25T19:56:23Z | |
dc.date.issued | 2006 | |
dc.department | Abant İzzet Baysal Üniversitesi | en_US |
dc.description.abstract | Cardiovascular disorders such as decreased heart rate variability, orthostatic hypotension, and arrhythmias have been frequently observed in Parkinson's disease (PD) patients. In this study, authors measured P wave duration and dispersion in PD patients and controls. Twenty-three consecutive patients with idiopathic PD and sex-age matched 23 control subjects were included to the study. A 12-lead surface ECG was obtained from each participant. Maximum-minimum P wave duration and P wave dispersion (PWD) were measured in both groups. Maximum P wave duration was found to be higher in PD patients than controls (117 +/- 12 vs. 105 +/- 9 ms p=0.001). Minimum P wave duration was similar in PD patients and controls (64 +/- 11 vs. 63 +/- 11 msp=0.7). PWD in PD patients was also found to be higher than those of controls (53 +/- 11 vs. 43 +/- 10 ms p=0.0001). P wave duration and PWD did not significantly differ between PD patients taking anti-parkinsonian agents from those who were not (119113 vs. 116 +/- 13 ms p=0.4 and 55 +/- 11 vs. 52 +/- 11 ms p=0.5, respectively). Moreover, when the PD patients taking anti-parkinsonian agents were excluded from the study, PD patients had still higher P wave duration and PWD compared to controls (119 +/- 11 vs. 105 +/- 9 ms p=0.004, 52 +/- 10 vs. 43 +/- 10 ms p=0.009, respectively). In conclusion, we found that P wave duration and PWD were greater in PD patients compared to control subjects. (c) 2006 Elsevier Inc. All rights reserved. | en_US |
dc.identifier.doi | 10.1016/j.pnpbp.2006.02.011 | |
dc.identifier.endpage | 723 | en_US |
dc.identifier.issn | 0278-5846 | |
dc.identifier.issn | 1878-4216 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 16600454 | en_US |
dc.identifier.startpage | 718 | en_US |
dc.identifier.uri | https://doi.org/10.1016/j.pnpbp.2006.02.011 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12491/13278 | |
dc.identifier.volume | 30 | en_US |
dc.identifier.wos | WOS:000237598100019 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Pergamon-Elsevier Science Ltd | en_US |
dc.relation.ispartof | Progress in Neuro-Psychopharmacology & Biological Psychiatry | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.snmz | YK_20240925 | en_US |
dc.subject | atrial arrhythmia | en_US |
dc.subject | Parkinson's disease | en_US |
dc.subject | P wave dispersion | en_US |
dc.subject | P wave duration | en_US |
dc.title | Assesment of P wave duration and dispersion in Parkinson's disease | en_US |
dc.type | Review Article | en_US |